Here, we assessed the effectiveness of nasal immunization with PSPF plus Cp 090104 and CP-derived BLPs in protecting against secondary pneumococcal infection using a well-established superinfection model with poly(I:C) and S. pneumoniae [10]. The gene discussed is CP; the disease is pneumococcal infection.